A team from the Institute of Neurosciences in Alicante (CSIC - UMH) has developed and patented a treatment for social disorders, such as anxiety or extreme introversion. It is based on the use of hormones that the brain naturally produces and which, as they have discovered, can regulate behavioral responses related to social interaction.

A team from the Institute of Materials Science of Barcelona (ICMAB) of the CSIC has developed carbon nanocapsules filled with enriched lithium compounds, which can be applied in Neutron Capture Therapy (NCT) for cancer treatment. They are now seeking industrial partners to continue the already patented development.

A team from ITEFI CSIC has developed an ultrasound system that allows the generation of cellular clusters in the form of spheres for in vitro studies. It enables the straightforward creation of stable three-dimensional cell cultures in just a few minutes.

A multicentre study led by the CSIC has developed a biomaterial based on the eggshell membrane, which takes advantage of its natural qualities to obtain a biohybrid material with future applications in guided bone regeneration and pulp capping.

The Laboratory of cancer bioinformatics and functional genomics from the Cancer Research Centre, a joint centre of the CSIC and the University of Salamanca (USAL), has designed a risk predictor for breast cancer patients using machine learning techniques. It allows the identification of genes associated with survival and risk of patients. The new test could be easily translated into the clinical practice, given that its development cost is similar to other routine techniques.

The CSIC and the Miguel Hernández University have developed a basket for in vitro tissue analysis. It enables to fix the sample and allowing its transport between wells without damaging it. It has an optimised design that allows the replacement of the mesh, the maximum use of the surface of the well and an efficient use of the reagents used.

Scientists at the Centre for Molecular Biology (CBM), joint center of the CSIC and the UAM, have developed antibodies that neutralise the SFRP1 protein, which according to recent studies is a crucial player in the pathogenesis of Alzheimer's disease and a promising therapeutic target. The aim is to obtain a drug that can delay the progression of the disease. Now they are searching for partners to scale-up the trial for clinical use.

A scientific team has developed new hydrogels that serve as 3D culture systems for immune cells and organoids. They allow a higher rate of cell growth than traditional cultures. Among other applications, the team is focusing on growing cells for immunotherapies and obtaining mini-organs for pre-clinical trials.